Anemia News and Research

RSS
Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.
Ligand Pharmaceuticals announces launch of redesigned Web site

Ligand Pharmaceuticals announces launch of redesigned Web site

GSK confirms FDA advisory committees' vote to allow Avandia to remain on the market

GSK confirms FDA advisory committees' vote to allow Avandia to remain on the market

Gene therapy represents safe alternative to current cures for blood disorder β-thalassemia

Gene therapy represents safe alternative to current cures for blood disorder β-thalassemia

New research shows Alzheimer's disease may increase risk of other potentially disabling health conditions

New research shows Alzheimer's disease may increase risk of other potentially disabling health conditions

Protalix BioTherapeutics' taliglucerase alfa for Gaucher disease granted French ATU

Protalix BioTherapeutics' taliglucerase alfa for Gaucher disease granted French ATU

FDA accepts Protalix's taliglucerase alfa NDA, assigns PDUFA action date

FDA accepts Protalix's taliglucerase alfa NDA, assigns PDUFA action date

Medivir reports 24-week interim Phase 2b results of TMC435 in treatment-naïve patients with HCV genotype-1

Medivir reports 24-week interim Phase 2b results of TMC435 in treatment-naïve patients with HCV genotype-1

FDA accepts to review sNDA for SPRYCEL for treating adult patients with CML

FDA accepts to review sNDA for SPRYCEL for treating adult patients with CML

Musashi 2 protein predicts progression of AML and CML, identify researchers

Musashi 2 protein predicts progression of AML and CML, identify researchers

Researchers report how mature red blood cells form

Researchers report how mature red blood cells form

Rockwell Medical completes End of Phase II meeting with FDA regarding SFP

Rockwell Medical completes End of Phase II meeting with FDA regarding SFP

Web sites that promote anorexia raise concern

Web sites that promote anorexia raise concern

Heart patients treated for lymphoma at increased risk of cardiac problems

Heart patients treated for lymphoma at increased risk of cardiac problems

Fera Pharmaceuticals launches Neptazanetm tablets for reducing intraocular pressure

Fera Pharmaceuticals launches Neptazanetm tablets for reducing intraocular pressure

Shire presents positive data from TKT-025 EXT Phase I/II study for VPRIV in type 1 Gaucher disease patients

Shire presents positive data from TKT-025 EXT Phase I/II study for VPRIV in type 1 Gaucher disease patients

Clemizole can yield high-level synergy with protease inhibitor class: Research

Clemizole can yield high-level synergy with protease inhibitor class: Research

HL patients with heart disease at increased risk of hospitalization for cardiac complications after treatment

HL patients with heart disease at increased risk of hospitalization for cardiac complications after treatment

Allogeneic stem cell transplant holds promise for treatment-resistant chronic lymphocytic leukemia

Allogeneic stem cell transplant holds promise for treatment-resistant chronic lymphocytic leukemia

Afinitor more than doubles progression-free survival in advanced pancreatic NET: Study

Afinitor more than doubles progression-free survival in advanced pancreatic NET: Study

Eisai reports preliminary results from Dacogen for Injection Phase III study in AML

Eisai reports preliminary results from Dacogen for Injection Phase III study in AML

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.